News NICE recommends cannabinoid med for severe epilepsy Global biopharma Jazz Pharmaceuticals’ Epidyolex/Epidiolex (cannabidiol), developed by GW Pharmaceuticals and now part of Jazz, has received
News Jazz breaks ground on $100m UK plant for cannabinoid drugs Jazz Pharma has started construction of a manufacturing facility in the UK that will be used to manufacture cannabinoid drugs from its recently
News NICE backs NHS funding for two cannabis-based drugs for firs... NICE has recommended two of GW Pharma's cannabis-based medicines, the first time that medicines derived from the plant have been recommended for NHS funding.
News GW launches cannabis-based epilepsy drug in US GW Pharmaceuticals is bullish about the company’s prospects following the launch of its cannabis-based medicine for a rare form of childhood epilepsy.
News PBM reform dropped in Congress' funding package Proposed reforms to the regulations for PBMs were dropped from the US Congress' end-of-year bill to provide funding to the federal government.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.